Navigation Links
Emerging pharmaceutical platform may pose risks to retinal health
Date:10/11/2011

LEXINGTON Ky. (Oct. 11, 2011) According to new research by University of Kentucky investigators, an emerging pharmaceutical platform used in treating a variety of diseases may produce unintended and undesirable effects on eye function. The paper, "Short-interfering RNAs Induce Retinal Degeneration via TLR3 and IRF3", appears in the current online edition of the journal Molecular Therapy, a publication of the Nature Publishing Group and the American Society of Gene and Cell Therapy.

"Short-interfering RNA (siRNA) technology has been regarded as one of the most exciting emerging platforms for new pharmaceuticals, said Dr. Jayakrishna Ambati, professor of physiology, and professor and vice chair of ophthalmology and visual sciences at UK.

To this point, siRNA drugs have been the subject of clinical trials past and present for a variety of disorders including: cancers, viral respiratory infections, hypercholesterolemia, macular degeneration, diabetic retinopathy and glaucoma. Major obstacles to realizing the therapeutic potential of siRNAs include delivery of the drug into cells and a generic suppression of blood vessel growth through immune activation, as shown by a 2008 paper from the Ambati group in the journal Nature.

"We now show a new undesirable effect of siRNAs that are 21 nucleotides or longer in length: these siRNAs, regardless of their sequence or target, can cause retinal toxicity. By activating a new immune pathway consisting of the molecules TLR3 and IRF3, these siRNAs damage a critical layer of the retina called the retinal pigmented epithelium (RPE). Damage to the RPE cells by siRNAs can also lead to secondary damage to the rods and cones, which are light-sensing cells in the retina," said Ambati.

The scientists' findings indicate that caution should be applied when designing or using siRNAs intended for either direct application to the eye, or intended for use in a way that may allow the drug to access the eye.

"Another novel aspect of this research is that the RPE degeneration caused by siRNAs resembles the pathology seen in the advanced form of age-related macular degeneration called geographic atrophy, said Ambati. "As there are few models of geographic atrophy, which affects millions of people worldwide, this paper provides an important advance for research in developing new treatments for this disease."

Because the research shows that siRNAs shorter than 21 nucleotides in length can evade the TLR3-IRF3 off-target immune response, it may be possible to achieve therapeutic effects without retinal damage by designing shorter siRNAs.


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
859-323-2394
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Georgia Tech researchers receive 3 NSF Emerging Frontiers awards
2. ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer
3. ATS issues report on emerging issues in HIV-associated pulmonary disease
4. Emerging drug class may enhance red blood cell production in anemic patients
5. New Society for Social Neuroscience to help guide emerging field
6. Live streaming of emerging brain science and health news
7. Emerging E. coli strain causes many antimicrobial-resistant infections in US
8. Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine
9. Experts explore emerging evidence linking diabetes and cancer
10. Second volume of groundbreaking Emerging Model Organisms series is released
11. Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... In response to recent growth and a demand ... and Blindness (NELV&B) , announces the opening of a new low vision showroom in ... impairments to get assessments, hands-on experience and training with low vision and blindness devices ...
(Date:5/1/2016)... ... May 02, 2016 , ... Avid collector, Andrew Hawley ... Post Pavilion in Columbia, Maryland concert posters. Dail Beeghley hit a poster design ... on August 16. According to Hawley, “The Pavilion was built to host the ...
(Date:5/1/2016)... ... 01, 2016 , ... ProBrand Reveal Volume 2 is a set of versatile and smooth logo ... keyframeless animations, users can easily create a unique logo reveal in just a matter of ... presets. Use these title presets to add a uniquely animated logo to any photos or ...
(Date:4/30/2016)... (PRWEB) , ... May 01, 2016 , ... Serenity Recovery, ... to rehabilitation, has produced a new video that focuses on one of the more ... recent sessions and clips from interviews with a participating patients and the Yoga class ...
(Date:4/30/2016)... ... 30, 2016 , ... The Hacking Medicine Institute ... critically evaluate and rank health-focused applications and connected devices for better disease monitoring ... and accurate information to help accelerate patient and provider adoption of clinically proven ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... titled, "Skincare Devices Market - Global Industry Analysis, Size, ... to the report, the global skincare devices market was ... anticipated to expand at a CAGR of 10.1% from ... 2023. Browse the full Skincare Devices Market (Treatment ...
(Date:4/27/2016)... 27, 2016  Bayer Animal Health today announced ... the University of Florida College of Veterinary Medicine, ... in Communication Award (BECA). Brittany was selected from ... a total of $70,000 in scholarship funds through ... Bayer has provided a total of $232,500 in ...
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
Breaking Medicine Technology: